Dr. Maria Marioli

Maria Marioli is a Principal Scientist and Group Lead in Nanomedicine at Ardena. With over 15 years of experience in analytical chemistry and pharmaceutical development, Maria specializes in the characterization of complex drug products, including nanoparticles and microparticles. 

Her expertise spans advanced liquid-phase separation techniques, building on her foundational research in field-flow fractionation, and the development of robust analytical methodologies essential for drug product development.

Throughout her career, Maria has held key scientific roles at Roche and Teva Pharmaceuticals before joining Ardena, where she now leads research efforts in nanomedicine. 

Maria holds a Ph.D. in Analytical Chemistry from the University of Amsterdam and continues to drive innovation in the field, with recent work focusing on advancements in AF4-DLS detection for pharmaceutical applications.

Rob van der Weegen

Rob van der Weegen is Principal Scientist and Group Lead at Ardena. He specializes in GMP-compliant process development and scale-up of complex nanoscale therapeutic modalities supporting clinical studies and future commercial manufacturing.

Rob joined Ardena in 2018 as a Process Development Scientist in the field of Nanomedicines. Since then, he has focused on supporting process development and manufacturing scale-up activities for advanced therapeutic programs within GMP-regulated environments. Prior to joining Ardena, he completed a two-year postdoctoral position in Paris specializing in polymer and materials sciences.

Rob obtained his PhD in Supramolecular Chemistry from Eindhoven University of Technology in 2015.